EASL Studio - S3E16 - Liver cancer in 2022: Wrap-up & outlook

Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:

why certain trials have failed whereas others have succeeded,
what we have learned about the connection between overall survival and progression-free survival as endpoints, and
how the systemic therapy of HCC has evolved.